Lung cancer slowed by Pfizer drug

	Tweet

A Pfizer Inc. kidney cancer drug has also shown promise in a small mid-stage trial as a treatment for the most common form of lung cancer, researchers said on Saturday.

The new study involved 63 patients whose non-small cell lung cancer had progressed despite earlier treatments with standard chemotherapy. All patients were then given Pfizer’s once-daily pill, Sutent, as a stand-alone treatment and continued to take it until their disease progressed.

Tumors shrank by at least 50 percent in six, or 9.5 percent, of the patients. They stopped growing in another 27, or 43 percent, of the patients, researchers said at the annual meeting of the American Society of Clinical Oncology being held in Atlanta.

Sutent was generally well tolerated, researchers said, with mostly mild to moderate side effects such as fatigue, nausea and shortness of breath.

Its effectiveness was comparable to that seen in separate earlier mid-stage trials of OSI Pharmaceuticals Inc’s Tarceva, a pill that had also been tested by itself among a similar group of lung cancer patients, said Dr. Bruce Johnson, director of thoracic oncology at the Dana Farber Cancer Institute.

“Both of these agents seem able to stabilize tumors and prevent them from growing,” said Johnson, who did not conduct the Sutent trial but was chosen to help explain its findings.

Johnson said Sutent’s ability to arrest tumor growth suggests it may prove able in larger trials to actually prolong lives of lung cancer patients, as Tarceva went on to do in its own late-stage trials that helped it win approval as a lung cancer treatment in the United States.

Both drugs block specific proteins that allow tumor cells to grow, and therefore cause far milder side effects than standard cancer treatments that also harm healthy tissue as they go after tumor cells.

“Any time you have well-tolerated agents like Tarceva and Sutent that can shrink tumors by themselves, they become candidates for use with standard chemotherapy,” Johnson said, a big potential use of the two medicines.

U.S. regulators in January approved Sutent, whose chemical name is sunitinib, to treat kidney cancer as well as a rare stomach and intestinal cancer known as GIST.

Larger trials will be needed to conclusively establish Sutent’s effectiveness against lung cancer, the most common cause of death from cancer in both men and women.

Cigarette smoking is the main cause of about 90 percent of lung cancer cases in men and about 70 percent of cases in women, according to the Merck Manual.

RELATED STORIES:
Working with mustard gas linked to lung cancer   Study Shows Minimally Invasive Lung Surgery Has Low Risk   Lung cancer research concludes that early diagnosis as key for improving survival   New test predicts if lung cancer will spread   Vitamins don’t reduce risk of lung cancer   New lung cancer test predicts survival   Lung cancer screening often yields false positives   Cancer risks of eating red and processed meat   CT screening can identify curable lung cancers   New lung cancer staging system revealed   UT Southwestern research uncovers genetic link between emphysema, lung cancer   Lung cancer patients may live longer with Alimta   New clinical trial for patients with asbestos-associated lung cancer   Inhaled drug may prevent lung cancer: study   Chest x-rays detect early lung cancer   Antibodies may point to early lung cancer   University of Colorado Cancer Center test helps reduce risk of death in advanced lung cancer   Narrow-band imaging increases specificity of early lung cancer detection   Women with lung cancer have better lung function than men   Scientists Identify New Gene Associated with Lung Cancer   Lung cancer killing more women in Europe   Gene variations directly link inflammation to an increased risk for lung cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]